Plasma lipoprotein(a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay

Clinica Chimica Acta

Volumn 253, Issue 1-2, 1996, Pages 21-35

  Contois, John H ^a,b,d   Lammi Keefe, Carol J ^b   Vogel, Silke ^b   McNamara, Judith R ^a   Wilson, Peter W F ^c   Massov, Tatyana ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

Cholesterol; Coronary heart disease; Epidemiology; Lipoprotein(a); Lipoproteins

Indexed keywords

LIPOPROTEIN A;

ADULT; AGE; AGED; ARTICLE; AUTOMATION; CONTROLLED STUDY; FEMALE; HEART DISEASE; HUMAN; IMMUNOASSAY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TECHNIQUE; TURBIDIMETRY;

EID: 0030607138     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-8981(96)06341-3     Document Type: Article

References (59)

1. 1-lipoprotein in patients with coronary heart disease. Clin Genet 1974;6:230-235.
2. [2] Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-765.
3. [3] Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-23.
4. [4] Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494-1499.
5. [5] Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 1986;256:2540-2544.
6. [6] Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis 1986;62:249-257.
7. [7] Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Quinici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981;38:51-61.
8. [8] Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992;89:1040-1046.
9. [9] Genest JJ, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-2033.
10. [10] Genest JJ, Jenner JL, McNamara JR et al. Prevalence 7of lipoprotein(a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991;67:1039-1045.
11. [11] Genest J, McNamara JR, Ordovas JM et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
12. [12] Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199-204.
13. [13] Zenker G, Költringer P, Boné G, Niederkorn K, Pfeiffer K, Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986;17:942-945.
14. [14] Jürgens G, Költringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology 1987;37:513-515.
15. [15] Költringer P, Jürgens G. A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 1985;58:187-198.
16. [16] Pedro-Botet J, Sentí M, Nogués X et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke: role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 1992;23:1556-1562.
17. [17] Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 1993;24:965-969.
18. [18] Hoff HF, Beck GJ, Skibinski CI et al. Serum Lp(a) level as a predictor of vein graft srenosis after coronary artery bypass surgery in patients. Circulation 1988;77:1238-1244.
19. [19] Rantapää-Dahlqvist S, Wallberg-Jonsson S, Dahlén G. Lipoprotein(a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheumat Dis 1991;50:366-368.
20. [20] Nakata H, Horita K, Eto M. Alteration of lipoprotein(a) concentration with glycemic control in non-insulin-dependent diabetic subjects without diabetic complications. Metabolism 1993;42:1323-1326.
21. [21] Takegoshi T, Haba T, Hirai J, Kitoh C, Saga T, Yamazaki Y, Mabuchi H. Alterations of lipoprotein(a) in patients with diabetic nephropathy. Atherosclerosis 1990;83:99-100.
22. [22] Loscalzo J, Weinfield M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis Thromb 1990;10:240-245.
23. [23] Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301-303.
24. [24] Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation od endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-305.
25. [25] Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue type plasminogen-activator binds to and is inhibited by surface-bound Lp(a) and LDL. Biochemistry 1991;30:6671-6677.
26. [26] Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein(a) and the effect of β-carotene. Metabolism 1992;41:1215-1224.
27. [27] Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 1991;87:767-771.
28. [28] Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370:460-462.
29. [29] Glueck CJ, Glueck HI, Tracy T, Spars J, McCray C, Stroop D. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 1993;42:236-246.
30. [30] Garcia Frade LJ, Alvarez JJ, Rayo I et al. Fibrinolytic parameters and lipoprotein(a) levels in plasma of patients with coronary artery disease. Thromb Res 1991;63:407-418.
31. [31] Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990;85:1709-1715.
32. [32] Bersot TP, Innerarity TL, Pitas RE, Rail SC, Weisgraber KH, Mahley RW. Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein(a) and that cause lipid accumulation in macrophages. J Clin Invest 1986;77:622-630.
33. [33] Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301:1248-1251.
34. [34] Schaefer EJ, Lamon-Fava S, Jenner JL et al. Lipoprotein(a) levels and risk of coronary heart disease in men. J Am Med Assoc 1994;271:999-1003.
35. [35] Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444-453.
36. [36] Jauhianen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease: a nested case control study. Atherosclerosis 1991;89:59-67.
37. [37] Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. J Am Med Assoc 1993;270:2195-2199.
38. [38] Gaubatz JW, Cushing GL, Morrisett JD. Quantitation, isolation, and characterization of human lipoprotein(a). Methods Enzymol 1986;129:167-186.
39. [39] Wilson PWF, Christianson JC, Anderson K, Kannel WB. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring Study. J Am Med Assoc 1989;262:41-44.
40. [40] McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1-8.
41. [41] Warnick GR, Benderson J, and Albers JJ. Dextran sulfate-Mg+ + precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-1388.
42. [42] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
43. [43] Levine DM, Sloan BJ, Donner JE, Lorenz JD, Heinzerling RH. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res 1992;22:173-178.
44. [44] Seman LJ, Jenner JL, McNamara JR, Schaefer EJ. Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. Clin Chem 1994;40:400-403.
45. [45] Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 1985;5:265-272.
46. [46] Jenner JL, Ordovas JM, Lamon-Fava S et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 1993;87:1135-1141.
47. [47] Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Ciin Chem 1995;41:246-255.
48. [48] Panteghini M, Bonora R. Triglyceride interference with an immunoturbidimetric quantification of lipoprotein(a) in serum (letter). Clin Chem 1994;40:1601-1602.
49. [49] Levine DM, Parker TS, Sloan BJ, Ribary E. Triglyceride interference with an immunoturbidimetric quantification of lipoprotein(a) in serum (response). Clin Chem 1994;40:1602-1603.
50. [50] Levine DM, Parker TS, Sloan BJ, Heinzerling RH, Lorenz JD. Lp(a) and triglyceride levels are inversely correlated in patients who have undergone coronary artery bypass graft surgery (abstract). Clin Chem 1992;38:1061.
51. [51] Emancipator K, Elin RJ. Relationship between lipoprotein(a) and other indices of cardiovascular risk (abstract). Clin Chem 1991;37:924.
52. [52] Werba JP, Safa O, Gianfranceschi G, Michelagnoli S, Sirtori CR, Franceschini G. Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. Atherosclerosis 1993;101:203-211.
53. [53] Selinger E, Daliongevilie J, Davignon J. Apolipoprotein(a) is present in the triglyceride-rich fraction in type IV hypertriglyceridemia. Clin Biochem 1993;26:59-64.
54. [54] Sgoutas DS, Tuten T. Effect of freezing and thawing of serum on the immunoassay of lipoprotein(a). Clin Chem 1992;38:1873-1877.
55. [55] Kronenberg F, Lobentanz EM, Konig P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 1994;35:1318-1328.
56. [56] Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arteriosclerosis Thromb 1992;12:1214-1226.
57. [57] Helmhold M, Bigge J, Muche R et al. Contribution of the apo(a) phenotype to plasma Lp(a) concentration shows considerable ethnie variation. J Lipid Res 1991;32:1919-1928.
58. [58] Parra HJ, Luyeye I, Bouramoue C, Demarquilly C, Fruchart JC. Black-white differences in serum Lp(a) lipoprotein(a) levels. Clin Chim Acta 1987;167:27-31.
59. [59] Klausen IC, Beisiegel U, Menzel HJ, Rosseneu M, Nicaud V, Faergeman O. Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS study. Arteriosclerosis Thromb Vasc Biol 1995;15:1001-1008.